http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Li, Hong-Sheng,Chen, Jin-Hu,Zhang, Wei,Shang, Dong-Ping,Li, Bao-Sheng,Sun, Tao,Lin, Xiu-Tong,Yin, Yong Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.3
Objective: To evaluate the effect of intravenous contrast on dose calculation in radiation treatment planning for oesophageal cancer. Methods: A total of 22 intravein-contrasted patients with oesophageal cancer were included. The Hounsfield unit (HU) value of the enhanced blood stream in thoracic great vessels and heart was overridden with 45 HU to simulate the non-contrast CT image, and 145 HU, 245 HU, 345 HU, and 445 HU to model the different contrast-enhanced scenarios. 1000 HU and -1000 HU were used to evaluate two non-physiologic extreme scenarios. Variation in dose distribution of the different scenarios was calculated to quantify the effect of contrast enhancement. Results: In the contrast-enhanced scenarios, the mean variation in dose for planning target volume (PTV) was less than 1.0%, and those for the total lung and spinal cord were less than 0.5%. When the HU value of the blood stream exceeded 245 the average variation exceeded 1.0% for the heart V40. In the non-physiologic extreme scenarios, the dose variation of PTV was less than 1.0%, while the dose calculations of the organs at risk were greater than 2.0%. Conclusions: The use of contrast agent does not significantly influence dose calculation of PTV, lung and spinal cord. However, it does have influence on dose accuracy for heart.
One Improved RLWE-based FHE and Fast Private Information Retrieval
( Wei-tao Song ),( Bin Hu ),( Xiu-feng Zhao ) 한국인터넷정보학회 2019 KSII Transactions on Internet and Information Syst Vol.13 No.12
With the rapid development of cloud computing, it raises real questions on privacy protection, which greatly limits the use of cloud computing. However, fully homomorphic encryption (FHE) can make cloud computing consistent with privacy. In this paper, we propose a simpler FHE scheme based on ring LWE problem, with a smaller size of ciphertext and a lower noise-expansion factor for homomorphic multiplication. Then based on our optimized RLWE-based FHE scheme, we propose a fast single-database private information retrieval protocol, combining with batching and number theoretic transform technology.
KBTBD7, a novel human BTB-kelch protein, activates transcriptional activities of SRE and AP-1
( Jun Jian Hu ),( Wu Zhou Yuan ),( Ming Tang ),( Yue Qun Wang ),( Xiong Wei Fan ),( Xiao Yang Mo ),( Yong Qing Li ),( Zao Chu Ying ),( Yong Qi Wan ),( Karen Ocorr ),( Rolf Bodmer ),( Yun Deng ),( Xiu 생화학분자생물학회 2010 BMB Reports Vol.43 No.1
Tao Gu,Li‑Min Wang,Qiang Hu,Xiu‑Bing Liang,Dong‑Xing Fu,Yong‑Xiong Chen,Xin‑Ming Zhao,Yan‑Wei Sheng 대한금속·재료학회 2022 METALS AND MATERIALS International Vol.28 No.11
An equiatomic refractory high-entropy alloy (RHEA) NbMoTaWRe is prepared by mechanical alloying (MA) and sparkplasma sintering (SPS). The effects of mechanical alloying and sintering behaviors on the microstructure and propertiesof the RHEA are investigated. After ball-milling for 30 h, the metastable and supersaturated MA powders with the bodycenteredcubic (BCC) structure are obtained. Then, the MA powders are sintered using the SPS method under the sinteringtemperature range of 1700–1900 °C, and the C atoms and WC introduced by the MA process reacts with the metastable andsupersaturated Ta/Nb phase of the MA powers to form the face-centered cubic (FCC) structure (Nb, Ta)C particles alongthe BCC matrix boundaries during the SPS process. The NbMoTaWRe alloy sintered at 1800 °C consisted of BCC matrixand FCC-type (Nb, Ta)C particles has high compactness (porosity fraction is 0.32%), fracture strength (2630 MPa), plasticstrain (6.82%), and hardness (992 ± 20 HV). These excellent properties of this RHEA are mainly attributed to the combinationof multi-effects, including sintering densification, grain refinement strengthening from the refined sizes (3.80 μm) BCCmatrix, precipitation strengthening from the (Nb, Ta)C particles, solid solution strengthening from multi-principal elementsand interstitial solid solution strengthening from C atoms dissolving into BCC matrix.
Zhou, De,Xie, Wan-Zhuo,Hu, Ke-Yue,Huang, Wei-Jia,Wei, Guo-Qing,He, Jing-Song,Shi, Ji-Min,Luo, Yi,Li, Li,Zhu, Jing-Jing,Zhang, Jie,Lin, Mao-Fang,Ye, Xiu-Jin,Cai, Zhen,Huang, He Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.2
Aim: To analyze the significance of different clinical factors for prognostic prediction in diffuse large B-cell lymphoma (DLBCL) patients. Methods: Two hundred and twenty-seven DLBCL patients were retrospectively reviewed. Patients were managed with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen or rituximab plus the CHOP (RCHOP) regimen. Results: Lactate dehydrogenase (LDH), ${\beta}2$-microglobulin (${\beta}2$-M), B symptoms, Ann Arbor stage and genetic subtypes were statistically relevant in predicting the prognosis of the overall survival (OS). In the CHOP group, the OS in patients with germinal center B-cell-like (GCB)(76.2%) was significantly higher than that of the non-GCB group (51.9%, P=0.032). With RCHOP management, there was no statistical difference in OS between the GCB (88.4%) and non-GCB groups (81.9%, P=0.288). Conclusion: Elevated LDH and ${\beta}2$-M levels, positive B symptoms, Ann Arbor stage III/IV, and primary nodal lymphoma indicate an unfavorable prognosis of DLBCL patients. Patients with GCB-like DLBCL have a better prognosis than those with non-GCB when treated with the CHOP regimen. The RCHOP treatment with the addition of rituximab can improve the prognosis of patients with DLBCL.
Development of a position sensitive CsI(Tl) crystal array
Shi, Guo-Zhu,Chen, Ruo-Fu,Chen, Kun,Shen, Ai-Hua,Zhang, Xiu-Ling,Chen, Jin-Da,Du, Cheng-Ming,Hu, Zheng-Guo,Fan, Guang-Wei Korean Nuclear Society 2020 Nuclear Engineering and Technology Vol.52 No.4
A position-sensitive CsI(Tl) crystal array coupled with the multi-anode position sensitive photomultiplier tube (PS-PMT), Hamamatsu H8500C, has been developed at the Institute of Modern Physics. An effective, fast, and economical readout circuit based on discretized positioning circuit (DPC) bridge was designed for the 64-channel multi-anode flat panel PSPMT. The horizontal and vertical position resolutions are 0.58 mm and 0.63 mm respectively for the 1.0 × 1.0 × 5.0 ㎣ CsI(Tl) array, and the horizontal and vertical position resolutions are 0.86 mm and 0.80 mm respectively for the 2.0 × 2.0 × 10.0 ㎣ CsI(Tl) array. These results show that the CsI(Tl) crystal array with low cost could be applied in the fields of medical imaging and high-resolution gamma camera.
Sheng-Huei Yang,Ching-Ming Chien,Mei-Chin Lu,Yi-Hsiung Lin,Xiu-Wei Hu,Shinne-Ren Lin 생화학분자생물학회 2006 Experimental and molecular medicine Vol.38 No.4
Cardiotoxin III (CTX III), a basic polypeptide with 60 amino acid residues isolated from Naja naja atra venom, has been reported to have anticancer activity. CTX III-induced K562 cell apoptosis was confirmed by DNA fragmentation (DNA ladder, sub-G1 for-mation) and phosphatidylserine (PS) externalization with an IC50 value of 1.7 g/ml at 48 h. A mechanistic analysis demonstrated that CTX III-induced apop-totic cell death was accompanied by up-regulation of both Bax and endonuclease G (Endo G), and downregulation of Bcl-XL. CTX III had no effect on the levels of Bcl-2, Bid, XIAP survivin, and AIF proteins. CTX III treatment caused loss of the mitochondrial membrane potential (Ψm), release of mitochon-drial cytochrome c to the cytosol, and activation of both caspase-9 and -3. CTX III-induced apoptosis was significantly blocked by the broad-spectrum cas-pase inhibitor Z-VAD-FMK. However, CTX III did not generate reactive oxygen species (ROS) and talase, did not block CTX III-induced apoptosis in K562 cells. Modulation of Bax, Bcl-XL, and the Endo G proteins, release of mitochondrial cytochome c, and activation of caspase-3 and -9 all are involved in the CTX III-triggered apoptotic process in human leukemia K562 cells.